Publicacions
- 
                        Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Gene-Olaciregui N, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM and Helin K. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomasNATURE MEDICINE . 23(4): 483-492. Nº de cites: 424 
- 
                        Monterrubio C, Paco-Mercader S, Gene-Olaciregui N, Pascual-Pastó G, Vilà-Ubach M, Cuadrado-Vilanova M, Ferrandiz MM, Castillo-Ecija H, Glisoni R, Kuplennik N, Jungbluth A, de Torres C, Lavarino C, Cheung NV, Mora J, Sosnik A and Carcaboso AM. Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8JOURNAL OF CONTROLLED RELEASE . 255: 108-119. Nº de cites: 38 
- 
                        Salas S, Agut-Quijano T, Rovira-Zurriaga C, Canizo D, Lavarino C and García-Alix A. Infratentorial congenital glioblastoma multiforme. A rare tumour with a still unknown biologyREVISTA DE NEUROLOGIA . 63(9): 411-414. Nº de cites: 3 
- 
                        Pascual-Pastó G, Gene-Olaciregui N, Vilà-Ubach M, Paco-Mercader S, Monterrubio C, Rodriguez E, Winter U, Batalla-Vilacís M, Català-Mora J, Salvador-Hernandez H, Parareda A, Schaiquevich P, Suñol M, Mora J, Lavarino C, de Torres C, Chantada G and Carcaboso AM. Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of disseminationCANCER LETTERS . 380(1): 10-19. Nº de cites: 28 
- 
                        Hernandez-Muñoz I, Figuerola-Bou E, Sánchez-Molina S, Rodriguez E, Fernández-Mariño AI, Pardo-Pastor C, Bahamonde MI, Fernández-Fernández JM, García-Domínguez DJ, Hontecillas-Prieto L, Lavarino C, Carcaboso AM, de Torres C, Tirado OM, de Alava E and Mora J. RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-?B pathway, independently of the fusion oncoproteinOncotarget . 7(29): 46283-46300. Nº de cites: 12 
- 
                        Rodriguez-Hernandez CJ, Mateo-Lozano S, Garcia-López M, Casalà C, Briansó F, Castrejon N, Rodriguez E, Suñol M, Carcaboso AM, Lavarino C, Mora J and de Torres C. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigensOncotarget . 7(13): 16112-16129. Nº de cites: 17 
- 
                        Gomez-Gonzalez S, Castellano G, Mayol G, Queiros A, Martín-Subero JI and Lavarino C. DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insightsGenomics data . 5: 360-363. Nº de cites: 5 
- 
                        Monterrubio C, Paco-Mercader S, Vilà-Ubach M, Rodriguez E, Glisoni R, Lavarino C, Schaiquevich P, Sosnik A, Mora J and Carcaboso AM. Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived XenograftsPHARMACEUTICAL RESEARCH . 32(9): 2889-2900. Nº de cites: 10 
- 
                        Mora J, Cruz-Martínez O, Lavarino C, Rios J, Vancells M, Parareda A, Salvador-Hernandez H, Suñol M, Carrasco-Torrents R, Guillen-Quesada A, Mañé S and de Torres C. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7)CLINICAL & TRANSLATIONAL ONCOLOGY . 17(7): 521-529. Nº de cites: 14 
- 
                        Gomez-Gonzalez S, Castellano G, Mayol G, Suñol M, Queiros A, Bibikova M, Nazor KL, Loring JF, Lemos I, Rodríguez E, de Torres C, Mora J, Martín-Subero JI and Lavarino C. DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insightsEPIGENOMICS . 7(7): 1137-1153. Nº de cites: 40 
